je.st
news
Tag: valeant
Valeant secures financing for potential Salix bid: Bloomberg
2015-02-12 23:37:52| Biotech - Topix.net
Valeant Pharmaceuticals International Inc has arranged financing for a potential bid for bowel-drug maker Salix Pharmaceuticals Ltd , Bloomberg reported, citing people familiar with the matter. The acquisitive Canadian drugmaker will likely bid more than $150 per share for the company, Bloomberg said, quoting one of those people.
Tags: potential
bid
financing
bloomberg
Valeant raises offer for Dendreon assets to US$400 million to remain lead bidder
2015-02-05 18:29:47| Biotech - Topix.net
Valeant Pharmaceuticals International has raised its offer for the Provenge prostate cancer vaccine and other assets of U.S. drugmaker Dendreon Corp. by $100 million to $400 million. The Quebec-based company is the lead bidder in an auction supervised by a U.S. bankruptcy court.
Tags: offer
lead
million
remain
Valeant back in action with sights set on a smaller target
2015-01-31 13:37:25| Biotech - Topix.net
J. Michael Pearson, chairman of the board and CEO of Valeant Pharmaceuticals International Inc., gestures during their annual general meeting in Laval, Quebec May 20, 2014.
Valeant Pharma projects double-digit growth in sales, earnings per share in 2015
2015-01-08 17:21:17| Biotech - Topix.net
Valeant Pharmaceuticals International Inc. says it plans to focus on small to medium-sized acquisitions from privately owned companies in 2015 following an unsuccessful attempt to take over California-based Allergan. The Quebec-based company told analysts that it believes its blockbuster bid for the maker of Botox would have been successful if a higher bid hadn't emerged from Actavis, which agreed to pay US$66 billion in cash and stock.
Tags: share
sales
growth
projects
Exclusive: Valeant to drop deal-making in near term to cut debt, boost stock
2014-12-09 11:06:42| Biotech - Topix.net
After spending $19 billion on 40 acquisitions since 2008, the Canadian drugmaker is regrouping after failing last month to acquire Botox-maker Allergan Inc ( The new strategy, targeted for the next two to three quarters, may surprise some investors accustomed to Valeant's usual way of doing business. Speculation about Valeant's next takeover target has driven up shares in generic drugmaker Mylan Inc ( Valeant does not rule out pursuing deals where appropriate, but it is focused on its ability to pay down debt or buy back shares, said spokeswoman Laurie Little.
Sites : [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] next »